Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sevabertinib in Hepatic Impairment
NCT07102095Phase 1Completed
- Sponsor
- Bayer
- Start
- Jul 2025
- Primary completion
- Dec 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of sevabertinib in cancer, lung cancer and metastatic cancer (2 arms), sponsored by Bayer. Primary endpoints: Area under plasma concentration-time curve, Unbound area under plasma concentration-time curve and 2 more. Started Jul 2025; status: completed.
02
Drugs
sevabertinib
03
Conditions
cancerlung cancermetastatic cancer
Beyond the preview
Go deeper on NCT07102095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07102095.